Crossref
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
AME Clinical Trials Review · 2024
DOI: 10.21037/actr-23-36 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Lauren Tagliaferro Epler und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Epler, L. T., & Neal, J. W. (2024). Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-36
Vancouver
Epler LT, Neal JW. Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-36
BibTeX
@article{Epler2024,
author = {Epler, Lauren Tagliaferro and Neal, Joel W.},
title = {Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer},
journal = {AME Clinical Trials Review},
year = {2024},
doi = {10.21037/actr-23-36}
}
EUVIMED